Levo Therapeutics is a brand dedicated to advancing science and creating effective treatments for Prader-Willi Syndrome (PWS) through precision medicine. With a singular focus on understanding the pathophysiology of PWS, they strive to develop treatments that will make a significant difference in the lives of patients and their families. Prader-Willi Syndrome is a complex condition characterized by a false state of starvation, leading to challenges such as anxiety, compulsivity, hyperphagia, intellectual disability, and a high risk of obesity.

Occurring in approximately 1 in 16,000 births, the underlying cause of PWS is the lack of expression of paternally inherited genes on a small part of chromosome 15. Levo Therapeutics is currently exploring a potential new treatment for PWS through their Phase 3 trial, which evaluated LV-101 (intranasal carbetocin). They are also actively working on developing an earlier stage pipeline based on the emerging science of metabolic hormone regulation and gene activation in PWS.

As their name suggests, Levo Therapeutics aims to ease, comfort, mitigate, and alleviate the symptoms faced by individuals with PWS. Their mission is to provide effective solutions for patients in need